BCL2L11 and neuroblastoma: One interesting study demonstrated that neuroblastomas have increased levels of miR-17-5p, which inhibits p21 and BCL2L11 (a.k.a., BIM) expression, and that p21 downregulation is significant in tumors with MYCN amplification and a poor clinical outcome [132].